About Seqirus's Australian Operations
Seqirus, formerly bioCSL, manufactures and in-licenses, markets and distributes vaccines with particular focus on vaccines for the prevention and treatment of serious disease. We operate one of the world’s largest influenza vaccine manufacturing facilities and supply seasonal influenza vaccines to Australia and global markets.
In July 2015, bioCSL and the influenza vaccines of Novartis joined forces to create Seqirus, now the second largest influenza vaccine company in the world.
Working closely with public health authorities and the Australian Department of Health & Ageing we have used our influenza vaccine technology to develop and license a pandemic influenza vaccine providing biosecurity to Australia’s population in the event of an influenza pandemic such as the 2009 swine flu.We are Australia’s first line of defence against pandemic influenza.
In addition, we in-license a range of pharmaceutical products from our partner companies to ensure a comprehensive range of products are available to meet the needs of many Australians.
We manufacture a Snake Venom Detection Kit and antivenoms to protect Australia's community from envenomation by our most venomous creatures.
Seqirus also manufactures a range of immunohaematology products (diagnostic reagents) that are supplied to Australian laboratories to enhance the safety of blood transfusions for patients in Australia.
Our heritage underpins our strong commitment to research and development, reliability, safety and quality. This philosophy has resulted in the development of many life-saving products and allowed us to play a key role in the collaborative work that has delivered the world’s first vaccine against cervical cancer.
Seqirus's Australian operations are also a signatory to the Australian Packaging Covenant (APC). As part of our commitment to the goals and principles of the APC, an action plan has been developed with actions that will integrate the principles sustainable packaging and product stewardship into packaging design process. Access to additional information can be found on the APC website -
Download the latest APC report (1 July 2015 - 30 June 2016) for Seqirus
In Australia, Seqirus is a member of Medicines Australia (MA) and complies with the MA Code of Conduct. We have prepared the following reportable transfers of payment report for publication in accordance with Edition 18 of the MA Code of Conduct, and in a manner consistent with Australia’s Privacy legislation.
Seqirus HCP transparency report 2015-16 PDF
Seqirus HCP transparency report 2015-16 CSV